Brexogen
Cargo-controlled exosome therapeutics for incurable diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | KRW12.0b | Series C | |
| Total Funding | 000k | ||
Brexogen, founded in 2019 by CEO Dr. Soo Kim, is a South Korean biotechnology company specializing in regenerative medicine through exosome-based therapeutics. Kim, who has over two decades of expertise in stem cells and exosomes, established the company to address the quality control and mass production challenges limiting current exosome therapies. The firm is headquartered in Seoul, South Korea.
The company's core technology is its proprietary BG-Platform, which focuses on developing disease-specific treatments by controlling the biomacromolecule cargo within exosomes. This platform utilizes induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) to ensure a stable and homogenous production of pharmaceutical-grade exosomes. Brexogen's business model revolves around the research, development, and commercialization of these novel biopharmaceuticals. This includes forming strategic partnerships, such as the technology transfer and licensing agreement with BMI Korea for the exosome therapeutic BxC-I17e. The deal involves an upfront payment, milestone payments, and royalties on net sales, with BMI Korea handling manufacturing and commercialization for specific indications.
Brexogen's therapeutic pipeline targets several incurable diseases. Its lead candidate, BRE-AD01, is an exosome-based therapy for atopic dermatitis, which entered Phase 1 clinical trials in the U.S. after receiving FDA clearance in late 2022. Other key pipeline products include BRE-MI01 for myocardial infarction and BRE-NA01 for metabolic dysfunction-associated steatohepatitis (MASH). In addition to its pharmaceutical pipeline, Brexogen has commercialized exosome-based products for aesthetic applications, including BREXTEM-S for skin rejuvenation and BREXTEM-H for hair restoration. The company has secured significant funding through multiple rounds, including a Series C in September 2023, to advance its clinical trials and research.
Keywords: exosome therapeutics, regenerative medicine, stem cell technology, biotechnology, cargo control platform, atopic dermatitis, myocardial infarction, iPSC-MSC, cell-free therapy, biopharmaceuticals, drug development, clinical trials, pharmaceutical manufacturing, metabolic disease, skin rejuvenation, hair restoration, licensing agreements, South Korean biotech, BG-Platform, BRE-AD01